loading page

Comparison of safety and efficacy of combinations of Azilsartan-medoxomil/Chlorthalidone and Olmesartan-medoxomil /Hydrochlorothiazide among hypertensive patients: A meta-analysis and systematic review
  • +4
  • Mahima Khatri,
  • Satesh kumar,
  • Asad Ali Siddiqui,
  • Jordan Gonzalo Llerena Velasteguí,
  • Ahmad hayat,
  • Anees Ahmad,
  • Ajay Kumar
Mahima Khatri
Dow University of Health Sciences

Corresponding Author:[email protected]

Author Profile
Satesh kumar
Shaheed Mohtarma Benazir Bhutto Medical College
Author Profile
Asad Ali Siddiqui
Dow University of Health Sciences
Author Profile
Jordan Gonzalo Llerena Velasteguí
Pontificia Universidad Catolica del Ecuador
Author Profile
Ahmad hayat
Punjab Medical College
Author Profile
Anees Ahmad
Punjab Medical College
Author Profile
Ajay Kumar
Jinnah Sindh Medical University
Author Profile

Abstract

Aims: This study intends to compare AZI-M/CT’s efficacy and side effect profile to the OLM/HCTZ in hypertensive patients. Materials and methods: Online databases (PubMed, Google Scholar, and ClinicalTrials.gov) were searched until January 15, 2022, for original articles exploring the effects of AZI-M/CT on pertinent outcomes among hypertensive patients in contrast to OLM/HCTZ. Data on baseline characteristics and endpoints were extracted. Review Manager version 5.4.1 and STATA 16.0 were used for analyses. Risk ratios (RR) and the weighted mean differences (WMD) with corresponding 95% confidence intervals were calculated. Results: Four studies were included having 3146 patients in total (AZI-M/CT: 1931 and OLM/HCTZ: 1215). The pooled analysis exhibited that compared to OLM-HCTZ, mean DBP was significantly lower in the AZI-M/CT group (WMD –2.64 [-2.78, -2.51]; p= <0.00001, I2= 1%), whereas no significant differences were noted in mean SBP (WMD –2.95 [-6.64,0.73]; p= 0.12, I2=100%) and achievement of target blood pressure (RR 0.95 [0.84,1.07]; p= 0.36, I2= 80%). Additionally, the risk of any TEAE (RR 1.11 [1.03, 1.20]; p= 0.007, I2= 51%) and serious adverse events RR 1.58 [1.20, 2.08]; p= 0.001, I2= 11%) was significantly higher in the AZI-M/CT group. However, no significant differences were observed in the risk of mortality between the two groups (RR 0.74 [0.14, 3.91; p = 0.72, I2= 0%). Conclusions: Our pooled analysis indicates that AZI-M/CT is more efficient at lowering blood pressure in elderly hypertensive patients than OLM/HCTZ. However, given the limited number of studies, positive results should be discretely re-evaluated and require further research.